ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs AZD 5069 (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ACE
- 01 Oct 2019 Planned End Date changed from 1 Dec 2020 to 1 Aug 2021.
- 01 Oct 2019 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated